Biomarin Pharmaceutical Raises FY2024 Adj EPS Guidance From $2.60-$2.80 To $2.75-$2.95 Vs $1.65 Est; Affirms FY2024 Sales Guidance from $2.70B-$2.80B Vs $2.77B Est

Author: Benzinga Newsdesk | April 24, 2024 04:27pm

2024 Full-Year Financial Guidance (in millions, except % and EPS amounts) (Updated)

BioMarin does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking Non-GAAP financial measures to the most directly comparable GAAP reported financial measures because the company is unable to predict with reasonable certainty the financial impact of changes resulting from our strategic portfolio and business operating model reviews; potential future asset impairments; gains and losses on investments; and other unusual gains and losses without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. As such, any reconciliations provided would imply a degree of precision that could be confusing or misleading to investors.

Item		Provided February 22, 2024						Updated April 24, 2024
Total Revenues		$2,700		to		$2,800		No Change
Non-GAAP Operating Margin %		23 %		to		24 %		24 %		to		25 %
Non-GAAP Diluted EPS (1)		$2.60		to		$2.80		$2.75		to		$2.95

(1)	Non-GAAP Diluted EPS guidance assumes approximately 200 million weighted-average diluted shares outstanding.

Posted In: BMRN